Table 1.
Demographics and clinical characteristics of study participants
| HC | Active | Stable | NTZ | OCZ | |
|---|---|---|---|---|---|
| n = 20 | n = 16 | n = 14 | n = 17 | n = 14 | |
| Age, mean, SD, y | 37(13)a | 36(10) | 43(12) | 39(10) | 41(11) |
| % Female (n) | 75% (15)* | 69% (11) | 93%(13)* | 94%(16)* | 64%(9) |
| Clinical State | RRMS | RRMS | RRMS | RRMS | |
| Disease State | Activeb | Stable | Stable | Stable | |
| DD, median (IQR), mo | 22.5(2.5–56)# | 142.5(62.5–183) | 87(47.5–157.5) | 159.5(33–239.3)# | |
| EDSS, median, (IQR) | 1.5(0.3–2.4) | 1.5(0.0–4.1) | 1(0.0–3.0) | 3.3(1.5–4.5) |
DD disease duration, EDSS Expanded Disability Status Scale, IQR interquartile range, m month, SD standard deviation, y year
aOne undetermined value, not included in correlation analysis
b14 out of 16 (87.5%) patients have confirmed contrast enhancing lesion
*p < 0.002 HC vs. stable, HC vs. NTX, determined by Fishers exact test between pairs
#p = 0.007 Active vs. OCZ, determined by ANOVA with Tukey's multiple comparisons test